Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Neuroinflammation in PASC
NCT05656105Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DPA-714 in post-acute sequelae of SARS-CoV-2 infection (PASC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Measurement of regional brain TSPO levels using PET at 6 weeks. Started Nov 2023; status: recruiting.
02
Drugs
DPA-714
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05656105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656105.